JP2022525377A5 - - Google Patents

Info

Publication number
JP2022525377A5
JP2022525377A5 JP2022502795A JP2022502795A JP2022525377A5 JP 2022525377 A5 JP2022525377 A5 JP 2022525377A5 JP 2022502795 A JP2022502795 A JP 2022502795A JP 2022502795 A JP2022502795 A JP 2022502795A JP 2022525377 A5 JP2022525377 A5 JP 2022525377A5
Authority
JP
Japan
Prior art keywords
sequence number
includes sequence
protein according
cdrl2
cdrl3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022502795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525377A (ja
JP7379654B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/022671 external-priority patent/WO2020190737A1/en
Publication of JP2022525377A publication Critical patent/JP2022525377A/ja
Publication of JP2022525377A5 publication Critical patent/JP2022525377A5/ja
Application granted granted Critical
Publication of JP7379654B2 publication Critical patent/JP7379654B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022502795A 2019-03-15 2020-03-13 抗bcmaキメラ抗原受容体 Active JP7379654B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819068P 2019-03-15 2019-03-15
US62/819,068 2019-03-15
PCT/US2020/022671 WO2020190737A1 (en) 2019-03-15 2020-03-13 Anti-bcma chimeric antigen receptors

Publications (3)

Publication Number Publication Date
JP2022525377A JP2022525377A (ja) 2022-05-12
JP2022525377A5 true JP2022525377A5 (cg-RX-API-DMAC7.html) 2023-03-22
JP7379654B2 JP7379654B2 (ja) 2023-11-14

Family

ID=72520450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502795A Active JP7379654B2 (ja) 2019-03-15 2020-03-13 抗bcmaキメラ抗原受容体

Country Status (10)

Country Link
US (4) US10934337B2 (cg-RX-API-DMAC7.html)
EP (1) EP3938401A4 (cg-RX-API-DMAC7.html)
JP (1) JP7379654B2 (cg-RX-API-DMAC7.html)
KR (3) KR102930430B1 (cg-RX-API-DMAC7.html)
CN (1) CN113631575A (cg-RX-API-DMAC7.html)
AU (1) AU2020241428B2 (cg-RX-API-DMAC7.html)
CA (2) CA3158025C (cg-RX-API-DMAC7.html)
IL (1) IL285909B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021011196A (cg-RX-API-DMAC7.html)
WO (1) WO2020190737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
KR102930430B1 (ko) 2019-03-15 2026-02-26 카티전 테라퓨틱스, 인코포레이티드 항-bcma 키메라 항원 수용체
KR20220144327A (ko) * 2021-04-15 2022-10-26 주식회사 유틸렉스 Hla-dr 특이적 키메라 항원 수용체 및 이의 용도
AU2023216270A1 (en) * 2022-02-04 2024-08-15 Nkilt Therapeutics, Inc. Chimeric ilt receptor compositions and methods
US20250213694A1 (en) * 2022-04-03 2025-07-03 Shanghai Simnova Biotechnology Co., Ltd. Enhanced chimeric antigen receptor and use thereof
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025158437A1 (en) * 2024-01-24 2025-07-31 Sheba Impact Ltd. T-cell specific rna constructs
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2013059343A1 (en) 2011-10-17 2013-04-25 Massachusetts Institute Of Technology Intracellular delivery
AU2013246443B2 (en) * 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
AU2015292744C1 (en) * 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
US10383929B2 (en) * 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US11535662B2 (en) * 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN118853581A (zh) * 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
CN109265550B (zh) * 2018-09-25 2020-09-15 华东师范大学 Bcma抗体、嵌合抗原受体和药物
CN109293772B (zh) * 2018-09-25 2020-09-29 上海邦耀生物科技有限公司 靶向bcma蛋白的抗体、嵌合抗原受体和药物
KR102930430B1 (ko) * 2019-03-15 2026-02-26 카티전 테라퓨틱스, 인코포레이티드 항-bcma 키메라 항원 수용체

Similar Documents

Publication Publication Date Title
JP2021501579A5 (cg-RX-API-DMAC7.html)
JP2024504384A5 (cg-RX-API-DMAC7.html)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
JP2024175003A5 (cg-RX-API-DMAC7.html)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2020508303A5 (cg-RX-API-DMAC7.html)
HRP20240182T1 (hr) Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2020500538A5 (cg-RX-API-DMAC7.html)
JP2025131696A5 (cg-RX-API-DMAC7.html)
JP2015534982A5 (cg-RX-API-DMAC7.html)
RU2021103288A (ru) МОЛЕКУЛЫ СО СПЕЦИФИЧНОСТЬЮ В ОТНОШЕНИИ CD79 и CD22
NZ623347A (en) Novel anti-dr5 antibody
JP2011528902A5 (cg-RX-API-DMAC7.html)
NZ584726A (en) Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
JP2017528476A5 (cg-RX-API-DMAC7.html)
JP2019504032A5 (cg-RX-API-DMAC7.html)
JP2006512899A5 (cg-RX-API-DMAC7.html)
RU2016129274A (ru) Канинизированные мышиные антитела к человеческому pd-1
NZ603972A (en) Anti-fgfr2 antibodies
JP2025501775A5 (cg-RX-API-DMAC7.html)
JP2012504955A5 (cg-RX-API-DMAC7.html)
JP2025508066A5 (cg-RX-API-DMAC7.html)
JP2022529036A5 (cg-RX-API-DMAC7.html)
JP2022507253A5 (cg-RX-API-DMAC7.html)